Cargando…

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Feng, Yun, Tan, Yuan, Duan, Qianqian, Zhang, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015670/
https://www.ncbi.nlm.nih.gov/pubmed/35444936
http://dx.doi.org/10.3389/fonc.2022.863560
_version_ 1784688363298619392
author Li, Jian
Feng, Yun
Tan, Yuan
Duan, Qianqian
Zhang, Qin
author_facet Li, Jian
Feng, Yun
Tan, Yuan
Duan, Qianqian
Zhang, Qin
author_sort Li, Jian
collection PubMed
description A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different clinical outcomes which deserve concern. Herein, based on NGS panel analysis, we firstly described a 61-year-old woman with lung adenocarcinoma who harbored a novel MET exon 14 skipping (c.3004_3028+3del) concurrent MET amplification (copy number: 3.91) and benefited from Savolitinib treatment. Moreover, CytoTest MET/CCP7 FISH Probe (c-MET/CCP7 Ratio:1.41 and mean gene copy number:6) and qPCR which based on ABI 7500 also were performed to confirm these two MET alterations. After 2 months of Savolitinib treatment, the clinical evaluation was a partial response (PR). In summary, our finding not only expanded the spectrum of the MET exon14 variant (METex14). Targeted NGS analysis could improve detection of MET alterations in routine practice.
format Online
Article
Text
id pubmed-9015670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90156702022-04-19 Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib Li, Jian Feng, Yun Tan, Yuan Duan, Qianqian Zhang, Qin Front Oncol Oncology A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). Several MET exon 14 skipping alterations have been identified, but different MET exon splice variants tend to have different clinical outcomes which deserve concern. Herein, based on NGS panel analysis, we firstly described a 61-year-old woman with lung adenocarcinoma who harbored a novel MET exon 14 skipping (c.3004_3028+3del) concurrent MET amplification (copy number: 3.91) and benefited from Savolitinib treatment. Moreover, CytoTest MET/CCP7 FISH Probe (c-MET/CCP7 Ratio:1.41 and mean gene copy number:6) and qPCR which based on ABI 7500 also were performed to confirm these two MET alterations. After 2 months of Savolitinib treatment, the clinical evaluation was a partial response (PR). In summary, our finding not only expanded the spectrum of the MET exon14 variant (METex14). Targeted NGS analysis could improve detection of MET alterations in routine practice. Frontiers Media S.A. 2022-04-04 /pmc/articles/PMC9015670/ /pubmed/35444936 http://dx.doi.org/10.3389/fonc.2022.863560 Text en Copyright © 2022 Li, Feng, Tan, Duan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Jian
Feng, Yun
Tan, Yuan
Duan, Qianqian
Zhang, Qin
Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title_full Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title_fullStr Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title_full_unstemmed Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title_short Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
title_sort case report: a lung adenocarcinoma with brain metastasis harbored novel met 14 skipping alteration sensitive to savolitinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015670/
https://www.ncbi.nlm.nih.gov/pubmed/35444936
http://dx.doi.org/10.3389/fonc.2022.863560
work_keys_str_mv AT lijian casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib
AT fengyun casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib
AT tanyuan casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib
AT duanqianqian casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib
AT zhangqin casereportalungadenocarcinomawithbrainmetastasisharborednovelmet14skippingalterationsensitivetosavolitinib